Werbung
Werbung

PACB

PACB logo

Pacific Biosciences of California, Inc.

1.94
USD
Gesponsert
-0.10
-5.15%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

1.94

0.00
+0.26%

PACB Ergebnisberichte

Positives Überraschungsverhältnis

PACB übertreffen die 19 der letzten 39Schätzungen.

49%

Nächster Bericht

Datum des nächsten Berichts
11. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$42.48M
/
-$0.14
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+10.51%
/
+7.69%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+8.30%
/
-71.43%

Pacific Biosciences of California, Inc. earnings per share and revenue

On 05. Nov. 2025, PACB reported earnings of -0.13 USD per share (EPS) for Q3 25, beating the estimate of -0.15 USD, resulting in a 16.13% surprise. Revenue reached 38.44 million, compared to an expected 41.01 million, with a -6.27% difference. The market reacted with a -7.05% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.14 USD, with revenue projected to reach 42.48 million USD, implying an increase of 7.69% EPS, and increase of 10.51% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
For Q3 2025, Pacific Biosciences of California, Inc. reported EPS of -$0.13, beating estimates by 16.13%, and revenue of $38.44M, -6.27% below expectations.
The stock price moved down -7.05%, changed from $1.92 before the earnings release to $1.78 the day after.
The next earning report is scheduled for 11. Feb. 2026.
Based on 10 analysts, Pacific Biosciences of California, Inc. is expected to report EPS of -$0.14 and revenue of $42.48M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung